Companies partner to develop biologics-based lower back pain treatment

Eric Oliver -   Print  |

Drugmakers Grünenthal and Mesoblast entered into a partnership to develop a biologics-based treatment for chronic lower back pain.

The companies are developing and commercializing MPC-06-ID, a phase 3 allogeneic cell therapy candidate. The companies hope the therapy can treat chronic lower back pain caused by degenerative disc disease. If successful, Grünenthal will have commercialization rights to the drug in Europe and Latin America.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers